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ABSTRACT: Glycan–protein interactions control numerous biological events from cell-cell recognition 
and signaling to pathogen host cell attachment for infections. To infect cells, some viruses bind to immune 
cells thanks to DC-SIGN (dendritic cell [DC]-specific ICAM3-grabbing non-integrin) C-type lectin 
expressed on dendritic and macrophage cell membrane, via their envelope protein. Prevention of this 
infectious interaction is a serious therapeutic option. Here, we describe the synthesis of first water-soluble 
tetravalent fucocluster pseudopeptide-based thiacalixarene 1,3-alternate as viral antigen mimics designed 
for the inhibition of DC-SIGN, to prevent viral particle uptake. Their preparation exploits straightforward 
convergent strategies involving one pot Ugi four-component (Ugi-4CR) and azido-alkyne click chemistry 
reactions as key steps. Surface plasmon resonance showed strong inhibition of DC-SIGN interaction 
properties by tetravalent ligands designed with high relative potencies and β avidity factors. All ligands 
block DC-SIGN active sites at nanomolar IC50 preventing cis-cell infection by Ebola viral particles 
pseudotyped with EBOV glycoprotein (Zaïre species of Ebola virus) on Jurkat cells that express DC-
SIGN. In addition, we observed strong inhibition of DC-SIGN/human cytomegalovirus (HCMV)-gB 
recombinant glycoprotein interaction. This finding opens the way to the simple development of new 
models of water-soluble glycocluster-based thia-calixarene with wide-range antimicrobial activities.
INTRODUCTION
The ability of viruses to resist traditional drugs is a crucial problem in current antiviral therapy.1,2 The 
widely approved antiviral drugs act intracellularly. Unfortunately, their toxicity and the rapid mutation of 
viruses lie behind the development of viral drug-resistance, strongly decreases therapeutic relevance.3 
This dramatic crisis in health control is exacerbated by severe co-infections by different germs in 
immunocompromised patients (e.g. Mycobacterium/HIV-1,4 HCMV/HIV-1,5 etc.). Consequently, the 
design and straightforward access to novel efficient drugs with a broad spectrum of antimicrobial action 
regardless of the pathogen's structural nature or resistance range, is urgently required. It is possible to 
develop such drugs by targeting the neutralization of common extracellular infectious mechanisms such 
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3as glycan-protein interactions.6,7 Viruses (e.g. HIV-1,8 HCMV,9 Ebola,10 SARS coronavirus, dengue11), 
along with some bacteria and parasites (e.g. Mycobacterium,12 Leishmania13), use this kind of interaction 
for their attachment to host cells, a preliminary step for their uptake with the view of subverting 
intracellular biosynthetic processes to their replication.14 Typically, the tetrameric transmembrane DC-
SIGN C-type-lectin (dendritic cell [DC]-specific ICAM3-grabbing non-integrin) that is expressed at 
innate immune system macrophage and DC membranes, serves as a key receptor for viral antigen-
containing carbohydrates (e.g. DC-SIGN/viral glycoproteins such as HIV-1-gp120, HCMV-gB, Ebola-
GP etc.).6,7,14,15 It is a key target that has stimulate the design of inhibitors as new tools to overcome 
attachment of pathogen to host cells to hinder the infectious process. Inspired by some effective 
monomeric inhibitors of enzymes (e.g. Glycosidases, glycosyltransferases etc.),16, 17,18,19 small non-
carbohydrate molecules as µ-molar IC50 inhibitors of DC-SIGN have emerged (e.g. Quinoxalinone 
inhibitors…).20,21 Glycomimetics compounds, mimicking natural ligand but having better stability, 
represent also popular alternative extensively explored now to target C-type lectin.22,23,24 As wide range 
of lectins,25,26 DC-SIGN is a multimeric protein naturally endowed with moderate affinity for specific 
monovalent sugars (e.g. only millimolar IC50 inhibition with L-fucose).27,28 However, suitable 
multipresentation of sugars create synergistic multiple binding events that enhance the avidity (apparent 
affinity).28,29 Thus, the use of multivalent viral glycan mimics to target DC-SIGN is a virustatic option 
that has triggered the design and assessment of a large panel of potentially relevant multivalent scaffolds 
such as mannosylated polymers,30 proteins,31 peptides,32 dendrimers,33,34,28 gold nanoparticles,35 
fullerene,36 and recently, carbon nanotube hybridized fullerene.37 The models designed strongly inhibit 
DC-SIGN but their development often uses uncommon and sophisticated building blocks that are difficult 
to handle. p-tBu-thiacalixarene is one of the cheapest platforms used for many applications including the 
detection and separation of biologically important ions, and the synthesis of self-assembled coordination cages 
or multinuclear complexes.38 However, this molecule is under-exploited in the multivalent glycocluster field, 
despite its availability and simple transformation.39 Here, we describe the first method for straightforward 
synthesis of fucocluster 1 and 2 based on p-tBu-thiacalixarene 1,3-alternate (Figure 1A). We rationalized 
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4their design following data in the literature related to the structure of DC-SIGN, the preference basis of 
L-fucose rather than that of the widely used D-mannose epitope, and water-solubility. The last point is 
particularly important as it represents a challenging problem when thiacalixarene and their congeners are 
used as scaffolds. First, we assessed both fucoclusters 1 and 2 as DC-SIGN inhibitors by surface plasmon 
resonance (SPR) technology using BSA-mannotriose functionalized surface (BSA-manα1-3[manα1-
6]man). Such surface allows addressing DC-SIGN/polymannose surface interaction and is a mimic of the 
DC-SIGN binding to HIV-1-gp120, which harbor high mannose glycans. Then, we evaluated binding 
inhibition of DC-SIGN/HCMV gB recombinant glycoproteins. Finally we assessed both ligands with 
respect to DC-SIGN-dependent host cell entry and infection by experimental Ebola virus viral particles 
pseudotyped with the recently emerged Zaïre species (EBOV). For impact evaluation of the scaffold 
topology, we synthesized and similarly assessed p-tBu-calix[4]arene fucocluster 3, which has a cone 
conformation (Figure 1B).
RESULTS AND DISCUSSION
Rationalized design and synthesis of glycoclusters 1, 2 and 3. Like its calixarene congener,40 
thiacalixarene is highly hydrophobic.41 This compromises biological assessment in aqueous media.42 
Using calixarene analogues, this problem could be solved when a glycoconjugated alkyl spacer was linked 
to p-tBu-calix[4]arene via a peptide moiety.43 Consequently, we targeted glycoconjugate 1 and 2 based 
p-tBu-thiacalix[4]arene 1,3-alternate linked to a pseudopeptide-bearing spacer (Figure 1). The four 
pseudopeptide sequences and the four fucose units should be synergistically favorable to the water-
solubility of glycocluster 1, and largely to that of glycocluster 2, due to the hydrophilic 
glycylglycylhydroxamic acid groups. As for iron chelation, the hydroxamic acid groups could also play a 
role in iron depletion, as another therapeutic attack strategy, against iron-dependent microbes.44 In 
contrast, DC-SIGN have affinity for D-mannose and L-fucose in a Ca2+-dependent multivalent fashion, 
and both sugars could be considered natural epitope of DC-SIGN. Two adjacent sites of the four 
carbohydrate recognition domains (CRDs) of DC-SIGN arranged on a single face are separated by about 
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538 to 40 Å, whereas opposite sites lie about 61 Å apart (Figure 2A).45 Following the interactions of L-
fucose in fucosylated glycans, and mannose in high mannose with DC-SIGN, the predominant binding 
could be chelation and/or statistical binding rebinding. This ensure a high density of sugars around CRDs. 
Hydroxyl groups in position 3 and 4 of L-fucose or D-mannose are the main contributor to binding 
interactions,8 which probably explains non-selective L-fucose and D-mannose recognition. To avoid, or 
at least diminish, the inhibition of some mannose specific lectins, such as langerin,46 involved in the 
vaginal mucosa in the defense against HIV-1 infection, we decided to investigate L-fucose. Without a 
cooperative effect of other neighboring sugars in heteroglycocluster systems, langerin only recognizes 
this sugar inefficiently. Other mannophilic lectins of the innate defense system, such as the mannose 
binding lectin (MBL),47 could also be saved from inappropriate inhibition. Further reasons to advocate L-
fucose use include its possible synergistic involvement as a carbohydrate-specific signaling molecule 
through specific binding to DC-SIGN. This provides action against invading pathogens via the initiation 
of T-helper cell differentiation.48 Finally, the length of the spacer arm was rationalized via molecular 
mechanic (MMFF) prediction of the greatest possible separation between two fucose units (See SI, Figure 
S31). We stated that approximately 50 to 55 Å should be enough to cover the highest distance of about 
40 Å between two adjacent CRDs by folding, in the event of the chelation mechanism.45 Furthermore, 
fucoclusters 1 and 2 could be considered an assembly of two bivalent systems separated by a rigid core 
(Thiacalixarene). This echoes other reported rigid multivalent glycoclusters (e.g. the rods of Bernardi et 
al49). Both ligands also have the possibility of addressing two directional binding approaches toward DC-
SIGN (Figure 2B), which should be favorable statistically for efficient interaction with DC-SIGN. Taking 
into account all these structural considerations, we targeted cooperative effects to increase the strength of 
binding to DC-SIGN of the ligands we examined.
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6A. Targeted thiacalix fucoclusters 1,3-alternate 1 and 2
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Figure 1. New designed fucoclusters 1, 2 and 3 for inhibition of DC-SIGN dependent viral infections.
Figure 2. A. Distances between CRDs in DC-SIGN; B. Binding approaches to DC-SIGN of thiacalixarene 
fucoclusters 1 and 2; Distances between two fucose units were estimated via molecular mechanic 
(MMFF) prediction (See SI, Figure S31).
We synthesized fucocluster 1 and its tetrahydroxamic acid derivative 2 following the convergent strategy 
described in scheme 1. For the multivalent presentation of L-fucoside moieties, we used the previously 
described tetrachloroalkyloxy-p-tBu-thiacalixarene 1,3-alternate 5 that is readily obtained in 93 % yield 
from the commercially available cone conformation of p-tBu-thiacalix[4]arene 4 (path 1).50 The 
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7conventional azidation of molecule 5 gives the tetra-alkoxyazido-p-tBu-thiacalix[4]arene derivative 6 (in 
94% yield) as the sugar acceptor. This can easily be transformed into a glycoconjugate via a click 
chemistry reaction.39 To tailor the required distance between two sugars in an elongated conformation, 
we used a coupling association of propargyl amine and the commercially available 6-bromo-hexanoic 
acid obtained via the Ugi four-component reaction (Ugi-4CR). Following pathway 2, the one pot Ugi-
4CR took place in methanol at room temperature by mixing together amine and paraformaldehyde to form 
an imine intermediate. This reacts subsequently with bromo-carboxylic acid and isocyanatoacetate to give 
the propargyl-glycylglycinate derivative 7 in 67% yield following a well-known mechanism.51 The latter 
was fully characterized to be a mixture of rotamers identified by 13C NMR spectroscopy using three pairs 
of signals that are representative of carbonyl groups in a ratio of about 1/0.5 at 173.59/173.22, 
170.05/169.89 and 169.07/168.53 ppm.
The subsequent click chemistry of the tetraazido-thiacalixarene 6 with the Ugi adduct 7 was carried out 
successfully under CuSO4.5H2O/Na-ascorbate with a mixture of THF/MeOH/tBuOH under conventional 
heating, to give tetrabrominated glycylglycinate thiacalixarene 8. Due to the four glycylglycinate peptide 
moieties, this hybridized thiacalixarene seemed to demonstrate a strong interaction with acidic silica gel 
for migration. Consequently, neutralization with 1% NEt3 as the base was necessary to separate molecule 
8 in a 58% yield using an acetone/ethylacetate/cyclohexane mixture as the eluent. Subsequent azidation 
under conventional conditions (NaN3, DMF, 90 °C) gave an excellent yield (92%) of the tetrazido 
pseudopeptide derivative 9. To obtain the desired compound, we tried two pathways: firstly, we gathered 
the known per-O-acetylated-1-O-propargyl-α-L-fucoside 10 and the tetraazidothiacalixarene 9 under 
click chemistry conditions using CuSO4.5H2O/Na-ascorbate in a mixture of THF/H2O/tBuOH under 
conventional heating or using CuI/DIEA in acetonitrile under heating by microwaves. The last conditions 
are the preferred ones, since the reaction was rapid and gave a clean crude product containing 
fucoconjugate 11 as the main compound. This was separated in good isolated yield (62%), upon 
chromatography on neutralized silica gel. This fuco-tetramer is well-characterized by MS-ESI (m/z = 
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81853.1 [M+2Na]2+) and NMR spectroscopy. The 13C NMR spectroscopy for instance shows as main 
feature, the existence of rotamers, a consequence of conformational equilibrium that is widely 
encountered in peptoïde derivatives.52 This behavior has no magnetic impact on fucose carbon atoms, 
whose signals are all represented by a single peak in the 13C-spectrum. This facilitates their analysis (See 
SI, Figure S9). Unfortunately, a subsequent acetolysis reaction gave an unexpected mixture. This negative 
result arose from the second alternative reaction that uses the free O-propargyl α-L-fucoside 12 in the 
click chemistry step. Using CuI/DIEA in acetonitrile under microwave heat for 30 min, we obtained the 
targeted glycocluster 1 at a yield of 53 % from C18-reverse-phase chromatography with a suitable 
H2O/CH3CN eluent gradient. To transform the attached ester functions into hydroxamic acid groups that 
are more favorable to solubility in water, we reacted cluster 1 with a large excess of aqueous 
hydroxylamine and a catalytic amount of potassium cyanide in methanol, at room temperature. The cluster 
2, which derived from this was easily obtained at a yield of 54% after C18-reverse-phase chromatography 
with an H2O/CH3CN eluent gradient. Both compounds were characterized by NMR (See SI) and LC-MS 
that shows high purities and respective parent ions at m/z = 1578.98 [M+2H]2+ and m/z =1053.39 
[M+3H]3+ for molecule 1, and m/z = 1581.52 [M+2H]2+ and m/z = 1054.45 [M+3H]3+ for molecule 2 
(See SI, Figures 25-28). 
To evaluate the topological impact on DC-SIGN inhibition, we subsequently synthesized p-tBu-
calix[4]arene fucocluster 3 using the same strategy (Schema 2). We started with the well-known cone 
conformation of tetraazido-propyloxy-p-tBu-calix[4]arene 1353 and the click chemistry reaction with Ugi-
adduct 7. We obtained tetrabromoalkyl-pseudopolypeptide 14 at a yield of 57%. Subsequent azidation 
gave the tethered azidoalkylpolypseudopeptide 15 in an almost quantitative amount. After click chemistry 
with propargyl fucoside 12, the latter gave the expected fucocluster 3 at a yield of 49%. The structure of 
3 was fully characterized by LC-MS using two parent ions at m/z = 1542.61 [M+2H]2+ and m/z = 1028.92 
[M+3H]3+ (See SI, Figures 29-30), and in 1H-NMR the cone conformation was characterized by the AB 
system of bridged ArCH2Ar. This gave two doublet signals at 3.15 and 4.32 ppm with a JAB coupling 
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9constant of about 12 Hz. As expected, all three glycocluster-based thiacalixarene and calixarenes 1, 2 and 
3 obtained respectively in overall yields of 25% (5 steps), 13% (6 steps) and 15% (5 steps), are highly 
water soluble, which allows their biological assessment in aqueous media.
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Scheme 1. Convergent strategy for synthesis of fucoclusters 1 and 2 using two key component, the Ugi 
adduct 7 and the tetraazido-thiacalixarene 6. i. 1-Bromo-3-chloro-propane, K2CO3, refluxed acetone; ii. 
NaN3, DMF, 90 °C; iii. MeOH, rt, 24h; iv. CuSO4.5H2O/Na-ascorbate, H2O/THF/tBuOH, 60 °C, 3h, or 
CuI/DIEA, CH3CN, MW, 30 min; v. MeONa, MeOH, rt; vi. NH2OHaq, KCNcat, MeOH/THF, rt.
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Schema 2. Synthesis of p-tBu-calix[4]arene fucocluster 3 via click-chemistry of UGI adduct 7 and 
tetraazidopropyloxy-p-tBu-calix[4]arene 13. i. CuSO4.5H2O/Na-ascorbate, H2O/THF/tBuOH, 60 °C, 3h, 
or CuI/DIEA, CH3CN, MW, 30 min; ii. NaN3, DMF, 90 °C.
Biological assessment
SPR measurement of DC-SIGN/BSA-man interaction in the presence of clusters 1, 2 and 3. Here we 
report the examination of the recognition behavior of ligands 1, 2 and 3, as well as the efficiency of the 
scaffold, for the inhibition of the extracellular domain (ECD) of DC-SIGN binding using a SPR 
competition assay. The sensor surface was grafted by bovine serum albumin protein bearing man1-
3α[man1-6]man trisaccharide as a high mannose mimic of the HIV-1-gp120 glycoprotein (BSA-man).42 
Glycoconjugate affinities were determined by competition experiments following the reported 
procedure54 by co-injection of 20 µM of DC-SIGN ECD and increasing concentrations of compounds 1, 
2 or 3 onto BSA-man. For sensorgrams of L-fucose as a positive monovalent control and for the three 
fucoclusters, see respectively tables 1, 2, 3, and 4 in SI. Figures 3A and 3B, respectively, show the 
inhibition curves and the corresponding IC50. These demonstrated better apparent affinities with CRDs of 
DC-SIGN for fucocluster 1, with an IC50 = 17 µM and multivalent power amplification represented by 
relative potency (rp = IC50(α-L-fucose)/IC50(1)) of about 120, with a high β avidity factor (β = IC50(1)/Valency = 4) 
of about 30 compared to L-fucose (Table 1). The attachment of glycylglycyl-hydroxamic acid groups in 
fuco derivative 2 also keeps a favorable binding interaction with DC-SIGN. The IC50 is also strong (23.9 
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11
µM) and rp (IC50(α-L-fucose)/IC50(Ligand 2)) and β avidity factors (β = rp/Valency = 4) remain high (85 and 21 
respectively), indicating a tight interaction compared to that of monovalent L-fucose. This finding 
evidenced a highly favorable topology impact compared to similar recent fucosylated dendrimers 
displaying higher level of multivalency.55,56 For a better understanding of the phenomenon, we 
investigated water-soluble fucocluster 3 with the cone conformation that concentrates the four ligands at 
the down-rim of the calixarene ring. We observed a slight difference in IC50 values between clusters 1 (17 
µM), 2 (23.9 µM) and 3 (26.5 µM), suggesting that both scaffold conformation impact similarly on the 
binding interaction. The high avidity observed, is due to the interaction of the sugar cap with DC-SIGN 
in solution via chelating and/or statistical binding rebinding mechanisms. Thiacalixarene or calixarene 
moieties contribute to the interaction with DC-SIGN by inducing high sugar densities via directional 
orientation of the sugar within a given set of distances between L-fucose units. Such results are reached 
with only four natural sugar units grafted onto the unusual thiacalixarene scaffold through an easy 
synthetic strategy that could be of interest in drug development. Importantly, inhibitory potencies towards 
DC-SIGN using fucoclusters 1 and 2 are around twenty times higher than other scaffolds with four natural 
ligands (D-Mann) or than highly O-fucosylated dendrimers.57,58 We have demonstrated that DC-SIGN 
can be strongly inhibited, suggesting that a new generation of antiviral glycocluster-based thiacalixarene 
and calixarene scaffolds is possible. Results obtained with recombinant gB of the human cytomegalovirus 
(HCMV) envelope and against cis-infection of EBOV, the Zaïre species of Ebola virus (see below) 
supported this conclusion.
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Figure 3. A. Inhibition curves of DC-SIGN binding to immobilized BSA-man (acting as an HIV-1-gp120 
mimic) with L-Fucose () and clusters 1 (), 2 (), or 3 (), using surface plasmon resonance (SPR). 
B. Histograms and the IC50 values of inhibition of DC-SIGN activity calculated for monovalent L-fucose 
and tetravalent fucoclusters 1, 2 and 3.
Table 1. IC50 of fucoclusters 1, 2 and 3 for inhibition of DC-SIGN/BSA-man interaction. The results 
highlight the weak impact of topology, supporting the statistical rebinding or chelation interaction with 
the three ligands.
Compound Valency IC50 (µM) Relative potency (rp) β avidity factor
L-fucose 1 2048 ± 17.3 - -
1 4 17 ± 0.4 120 30.12
2 4 23.9 ± 0.5 85.69 21.4
3 4 26.5 ± 0.5 93.58 19.32
rp = IC50(L-fucose)/IC50(Ligand 1, 2 or 3); β avidity factor = rp/n
Inhibition of HCMV recombinant gB /DC-SIGN-expressing U937 cell line by fucoclusters 1, 2 and 
3. Although HCMV is not as lethal as HIV-1(both viruses have spherical forms and highly mannosylated 
antigens) it causes lifelong infection in world population, serious congenital disease in new-borns and is 
responsible for dramatic chronic infections in immunocompromised individuals such as transplanted 
patients and those suffering from AIDS. As fin the case of HIV-1, there is no vaccine against HCMV, 
which in addition exhibits a growing resistance to existing treatments.59 It is also known that HCMV 
requires iron for its cytomegaly development60 and has the ability to penetrate a number of host cells and 
hijack their biochemical process for its replication.61 One of the most important glycoprotein antigen in 
this respect is the highly mannosylated envelope glycoprotein B (gB)62 used by HCMV to cross the 
external host cell membranes. Glycoprotein B is involved in two main ways: by interaction with DC-
SIGN as the main mechanism for DCs infection62,9 and by interaction with the host cell walls heparane 
sulfate to infect DCs and other cells.61,63 Here, we focused on DC-SIGN which interacts with gB64 in a 
similar manner as with the GP glycoprotein of Ebola virus or gp120 of HIV-1 during adhesion to host 
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cells, a step prior to infection. We demonstrated that gB/DC-SIGN binding is a fundamental interaction 
of the whole virus with DC-SIGN+ cells, ie monocyte-derived DCs (MDDC) or U937 transfectants 
harboring DC-SIGN,62 consequently its inhibition could be a serious mean to hinder HCMV trans-
infection. The 1, 2 and 3 fucoclusters seem to have the potential to inhibit HCMV trans-infection. The 
test used was based on the measurement of the interaction between human MDDC and one of their viral 
ligands, the recombinant form of gB. The inhibitors were tested with mannan as a positive control (Figure 
4A). Our expectations were met since the HCMV recombinant gB/DC-SIGN interaction was inhibited at 
micromolar IC50 for fucocluster 1 (1 µM) and at submicromolar IC50 for cluster 3 (0.777 µM). We can 
consider these two activities as being similar. In contrast, a striking nanomolar IC50 (34 nM) was reached 
with cluster 2-bearing hydroxamic acid groups (HAGs) (Figure 4A, Table 2). The three ligands show 
better inhibition than polymeric mannan, a known inhibitor of this interaction.64 However, cluster 2 with 
the hydroxamic acid bearing linker deserves special mention, with inhibition that is 144-fold higher than 
mannan, and respectively 29- and 22-fold than fucocounterpart 1 and calix cone 3 (Table 2). Another 
striking observations is the efficient activity of 2 compared to the recently reported weak inhibitors 
harboring mannose units such tetravalent mannocluster based mannose as scaffold (higher than millimolar 
IC50)65 or highly mannosylated polymer (89 mannose units, IC50 = 4.2 µM);65 Cluster 2 is a 123-fold 
stronger inhibitor than the latter. Blocking HCMV gB/DC-SIGN binding in the nanomolar range is 
exceptional and shows that 1, 3, and to a large extent the fucocluster 2 prototype, have good spatial 
distributions that efficiently block the CRD sites of DC-SIGN. This reflects the intrinsic pre-organization 
of the thiacalixarene scaffold that acts synergistically through the contribution of the sugar units and the 
linkers carrying hydroxamic acid groups in 2. The improved efficiency of glycocluster 2 might find its 
origin in another interaction, in addition to the one with DC-SIGN, with HCMV-gB itself thanks to the 
anionogenic property of the multiple hydroxamic acid assemblies. Indeed, It could mimick the HCMV-
gB interaction with the negatively charge glycosaminoglycan sulfates of host cell walls..61,63
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Figure 4. A. Inhibition curves of DC-SIGN/HCMV recombinant gB interaction obtained by flow 
cytometry with: a. Mannan, b. Fucocluster 1, c. Fucocluster 2 and d. Fucocluster 3. Duplicate experiment 
gave comparable results. B. Inhibition of EBOV pseudotyped virus cis-infection () using Jurkat cells 
expressing DC-SIGN. As reference VSV-GP (Vescicular Stomatitis virus envelope glycoprotein) () was 
used. Cells that do not express DC-SIGN were used as a negative control. EBOV inhibition by 
compounds: a. 1; b. 2; c. 3 are shown. The three graphs a, b and c correspond to the mean of two 
independent experiments performed in triplicate with error bars corresponding to the standard errors of 
the mean.
Table 2. Summary of IC50 obtained for Inhibition of Interactions of DC-SIGN/clusters 1, 2 and 3, DC-
SIGN/HCMV Recombinant gB and EBOV cis-Infection.
Compound Valency DC-SIGN/gB-HCMV 
interaction inhibition 
IC50 
Relative 
Inhibition/Mannan
Relative Inhibition 
of 2/1 and 2/3
EBOV 
IC50 (nM)
Mannan 15.5 µg/mL - -
1 4 1000 nM (3.155 µg/ml) 4.91 29/1 601.5
2 4 34 nM (0.107 µg/ml) 144 - 253.5
3 4 777 nM (2.400 µg/ml) 6.45 22/3 218
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Inhibition of EBOV cis-infection by clusters 1, 2 and 3. The Ebola filovirus that is responsible for 
severe hemorrhagic fever66,67 is dreaded worldwide due to its lethal action and the absence of efficient 
vaccines68 and efficacious anti-infection strategies.69,70 Of the five species identified by their region of 
origin, we were interested in the Zaire variant, now named Ebola virus (or EBOV) that causes up to 90% 
mortality and was responsible for the recent Ebola outbreak in West Africa.71,72 Several therapeutic 
approaches have been attempted against Ebola virus infections such as the use of monoclonal antibodies73 
or small molecules that interfere with viral replication. However, despite some success of these molecules 
in preclinical models using non-human primates, there are currently no data to support their clinical 
efficacy.74,75 The strategy of targeting an intracellular process is still threatened by the development of 
viral resistance, and the search for alternative strategies that would avoid such resistance remains limited. 
One possible unconventional approach is to prevent adhesion, communication and other infectious 
processes used by the virus, by acting exogenously. As DC-SIGN has been designed as a lead lectin with 
a function that is hijacked by EBOV for the recognition and subsequent infection of DC cells,76  much 
work has been focused on the development of efficient multivalent inhibitors of this lectin to hinder 
binding of the virus to DCs. Several molecules have been assessed for their activity against EBOV,36,58 
and the best of these were highlighted in a recent perspective article.36 However none was a glycocluster-
based thiacalixarene or calixarene. Thus, we assessed glycoclusters 1, 2 and 3 described in this paper 
against EBOV. Infection was performed on Jurkat cells (a T-lymphocyte cell line) expressing the DC-
SIGN receptor. Since Ebola virus does not infect T-lymphocytes, its entry into Jurkat cells is absolutely 
dependent on DC-SIGN.77 Jurkat DC-SIGN+ cells were plated in 96-well plates and incubated at room 
temperature for 20 min with one of the three glycoclusters, and then challenged with 10000 TCID (Tissue 
culture infectious dose) of a recombinant virus pseudotyped with the Ebola virus envelope glycoprotein 
that expresses firefly luciferase.78,79 After 48h, the cells were washed and lysed for a luciferase assay. The 
range of concentrations tested for the compounds was 1 nM–100 µM. As a control, an infection with 
VSV-G pseudo viruses (Vesicular stomatitis virus) was carried out under the same conditions. The 
infection with VSV-G is independent of the presence of the DC-SIGN receptor. The results of EBOV 
Page 15 of 31
ACS Paragon Plus Environment
Bioconjugate Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16
inhibition by fucoclusters 1, 2 and 3 are shown in figure 4B. Interestingly, all of compounds 1, 2 and 3 
exhibited strong inhibition of EBOV infection at an IC50 in the nanomolar scale (601.5, 253.5 and 218 nM 
respectively). It should be noted that fucocluster 3 is twice as effective as cluster 1 but acts quasi-equally 
to cluster 2. Also, molecules 2 and 3 that only have four fucose units are more potent and stronger 
inhibitors of DC-SIGN-mediated EBOV infection than dendrimers with high densities of mannose units 
(e.g. the Boltorn dendrimer with 32 mannose units, IC50 = 337 nM).76 This opens the way for further 
development of fucose-based antiviral thiacalixarene drugs against Ebola infection.
Conclusions
In conclusion, we have synthesized the first water-soluble thiacalix[4]arenes fucoclusters 1 and 2, which 
are potent inhibitors of DC-SIGN. The evaluation in SPR competition experiments showed a unique 
affinity of soluble DC-SIGN for these clusters that is stronger than those reported for some manno or 
fuco-dendrimers with higher densities of mannose or fucose units. This supports the importance of the 
inherent directional presentation of sugars by the thiacalixarene scaffold. Nevertheless, the 1,3-alternate 
conformation seems not to be decisive since a similar result was obtained with the cone conformation of 
fucocluster 3. This indifference with respect to conformation supports the possible occurrence of 
statistical association and/or chelation interaction with the possible existence of secondary interaction due 
to the functionalised linker. The latter interaction is probably responsible for the strong inhibition of both 
cis-infection by EBOV and of the interaction between recombinant HCMV gB and primary human cells 
like MDDC known to express DC-SIGN. The reached nanomolar avidity level in both cases may find its 
origin in a clustering binding mode, with the trans-membrane DC-SIGNs, in addition to the chelation 
and/or statistical rebinding observed in solution assays. Moreover, internalization of DC-SIGN upon 
binding, and its disappearance from the surface, may be also an enhancer of the inhibitory effect observed. 
Although these results need further investigation, it opens the way for further development of antiviral 
drugs based on these newly designed prototypes. The results of our research support also the conclusion 
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that anti-multi microbial treatment with a single drug is possible. We will investigated this in depth in our 
future program.
EXPERIMENTAL SECTION
1. Organic chemistry.
General methods. All chemical reagents were purchased from Sigma, Fisher (France) or TCI-Europe. 1H 
and DeptQ NMR spectra were recorded on 600 MHz Bruker spectrometers in appropriate deuterated 
solvents; chemical shifts are reported on the δ scale. All 13C NMR signals were assigned through C–H 
correlated HSQC spectra. TLC was performed on Silica Gel 60 F254, 230 mesh (E. Merck) with 
cyclohexane-EtOAc or EtOAc-MeOH, and spots were detected by vanillin–H2SO4 reagent. Preparative 
column chromatography was performed using 230–400 mesh Merck silica gel (purchased from Sigma). 
Flash chromatography was performed with Reveleris-Flash System apparatus with cartridge SiO2-normal 
phase or C18-reverse phase. Low resolution electrospray mass spectra (ESI-MS) in the positive or 
negative ion mode were obtained on Waters ZQ 4000 quadrupole instrument equipped with an 
electrospray (Z-spray) ion source. High resolution electrospray experiments (ESI-HRMS) were 
performed on a Waters Q-TOF Ultima Global hybrid quadrupole time-of-flight instrument, equipped with 
an electro-spray (Z-spray) ion source.
Methyl N-(6-bromohexanoyl)-N-(prop-2-yn-1-yl)glycylglycinate (7). Formaldehyde (0.145 g; 4.84 
mmol) and propargylamine (0.266 g; 4.84 mmol) in methanol (4 mL) were stirred at room temperature 
for 30 min. Then, methyl isocyanoacetate  (0.4 g; 4.036 mmol) and 6-bromohexanoic acid (0.944 g; 4.84 
mmol) were added. The resulted mixture was stirred at room temperature and followed by TLC until 
completion (36 h). After concentration, the residue was purified by flash chromatography 
(EtOAc/cyclohexane) affording the desired compound 7 as a yellow solid. Yield 0.973 g (67%); Rf = 0.25 
(SiO2, Cyclohexane/EtOAc : 3/2); ESI-MS: m/z = 385.0 [M+Na]+. 1H-NMR (CDCl3, 600 MHz), δ (ppm): 
-6.94-6.78 (m, 1H, NH), 4.17-4.08 (m, 4H, CH2C≡CH/NCH2CO), 4.04-3.96 (m, 2H, NHCH2CO), 3.70(s, 
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3H, OCH3), 3.49-3.25 (m, 2H, CH2Br), 2.51-2.22 ( m, 3H, CH2/ CH2C≡CH), 1.84 (m, 2H, CH2), 1.66 (m, 
2H, CH2), 1.46 (m, 2H, CH2). 13C-NMR (CDCl3, 150 MHz), δ (ppm): 173.5/173.2 (C=O), 170.0/169.8 
(C=O), 169.0/168.5 (C=O), 77.9 (CH2C≡CH), 73.3 (CH2C≡CH), 52.3 (OCH3), 49.4 (NCH2CO), 41.0 
(NHCH2CO), 38.7 (CH2), 36.0 (CH2), 33.6 (CH2), 32.5 (CH2), 27.7 (CH2), 23.9 (CH2). HRMS(ESI/Q-
TOF) m/z: [M + Na]+ calcd for C14H21BrN2O4Na 383.0582; found 383.0594.
Tetrabromo-tetramethylglycylglycinate pseudopeptide p-tBu-thiacalixarene 1,3-alternate 
derivative 8. To a stirred solution of compound 7 (0.48g; 1.32 mmol) and tetraazidopropyl-p-tBu-
thiacalix[4]arene 639 (0.318g; 0.301 mmol) in THF/tBuOH (7.5mL/15mL) was added a freshly prepared 
solution of Cu(I) (from CuSO4.5H2O (0.15 g) and sodium ascorbate (0.239 g) in H2O (15 mL)). The 
mixture was stirred for 3h at 60 °C. After solvent evaporation, the crude product was extracted with 
CH2Cl2 and washed with brine. The organic layer was dried on MgSO4 and concentrated. Compound 8 
was obtained after purification by column chromatography on silica gel (3/3/2: 
acetone/EtOAc/Cyclohexane, 1% N(Et)3) as a white solid. Yield 0.396 g (58%); Rf  = 0.43 (SiO2, 
acetone/EtOAc/Cyclohexane : 2/2/1 + 1% N(Et)3); ESI-MS: m/z = 1272.3 [M+2Na]2+. 1H-NMR (CDCl3, 
600 MHz), δ(ppm): 7.95-7.55 ( m, 8H , NH/CHtriazole), 7.27-7.21 (m, 8H, CHAr), 4.73-4.56 (m, 8H, CH2), 
4.28-3,90 (m, 40H, CH2), 3.70 (s, 12H, OCH3), 3.36 (t, 8H, CH2Br, J = 6.7 Hz ), 2.60-2.25 (m, 8H,CH2), 
1.87-1.79 (m, 8H, CH2), 1.74-1.54 (m, 16H, CH2), 1.54-1.39 (m, 8H,CH2), 1.01 (s, 36H, CH3). 13C-NMR 
(CDCl3, 150 MHz), δ(ppm): 174.0-168.8 (C=O), 156.3 (ArCOCH2), 146.3 (ArC(C(CH3)3)), 143.4 
(Ctriazole), 128.1 (ArCSCAr), 127.3 (CHAr), 122.9 (CHtriazole), 66.0 (CH2OAr), 52.3 ( OCH3), 51.6 (CH2), 
50.1 (CH2),47.8 (CH2), 44.6 (CH2), 42.5 (CH2), 41.0 (CH2), 34.1 (C(CH3)3), 32.5 (CH2), 31.0 (CH3), 30.0 
(CH2), 27.7 (CH2), 24.0 (CH2). HRMS(ESI/Q-TOF) m/z: [M+2Na]2+ calcd for C108H152Br4N20Na2O20S4 
1269.3451 found: 1269.3447.
Tetrazido-tetramethylglycylglycinate-pseudopeptide p-tBu-thiacalixarene 1,3-alternate derivative 
9. To a stirred solution of compound 8 (0.375g; 0.15 mmol) in DMF (12 mL) was added NaN3 (0.117g; 
1.79 mmol). After 12 h at 90 °C and evaporation, the crude product was extracted with CH2Cl2 and washed 
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with brine. The organic layer was dried on MgSO4 and concentrated. Compound 9 was obtained after 
purification by column chromatography on silica gel (3/3/2: acetone/EtOAc/Cyclohexane, 1% N(Et)3) as 
a yellow solid. Yield 0.324 g (92 %); Rf = 0.43 (SiO2, acetone/EtOAc/Cyclohexane : 2/2/1 + 1% N(Et)3); 
ESI-MS: m/z = 1196.0 [M+Na]2+. 1H-NMR (CDCl3, 600 MHz), δ (ppm): 8.00-7.56 ( m, 8H , 
NH/CHtriazole), 7.26-7.20 (s, 8H, CHAr), 4.71-4.49 (m, 8H, CH2), 4.28-3.89 (m, 40H, CH2), 3.69 (s, 12H, 
OCH3), 3.23(m, 8H, CH2N3), 2.64-2.22 (m, 8H,CH2), 1.87-1.79 (m, 8H, CH2), 1.74-1.56 (m, 16H, CH2), 
1.47-1.33 (m, 8H,CH2), 0.98 (s, 36H, CH3). 13C-NMR (CDCl3, 150 MHz), δ (ppm): 174.1-173.4 (C=O), 
170.4- 168.7 (C=O), 156.3 (ArCOCH2), 146.3 (ArC(C(CH3)3)), 143.6 (Ctriazole), 128.1 (ArCSCAr), 127.3 
(CHAr), 123.07 (CHtriazole), 66.1 (CH2OAr), 52.2 ( OCH3), 51.4 (CH2N3), 50.1 (CH2),47.5 (CH2), 44.5 
(CH2), 42.5 (CH2), 41.0 (CH2), 34.1 (C(CH3)3), 32.7 (CH2), 31.2 (CH3), 29.8 (CH2), 28.6 (CH2), 26.3 
(CH2). HRMS(ESI/Q-TOF) m/z: [M+2Na]2+ calcd for C108H152N32O20S4Na2 1195.5264, found: 
1195.5250.
Peracetylated tetramethylglycylglycinate-pseudopeptide p-tBu-thiacalixarene 1,3-alternate 
derivative 11. To a stirred solution of thiacalix 9 (0.2 g; 0.085 mmol) and acetylated α-L-fucose 10 (0.123 
g; 0.374 mmol) in THF/tBuOH (8mL/16mL) was added a freshly prepared solution of Cu(I) (from 
CuSO4.5H2O (0.042g) and sodium ascorbate (0.067g) in H2O (16 mL)). The mixture was stirred for 3h at 
60 °C. After solvent evaporation, the crude product was extracted with CH2Cl2 and washed with brine. 
The organic layer was dried on MgSO4 and concentrated. Compound 11 was obtained after purification 
by column chromatography on silica gel (3/3/1.5: acetone/EtOAc/cyclohexane, 1% N(Et)3) as a white 
solid. Yield 0.193 g (62%); Rf = 0.2 (SiO2, acetone/EtOAc/Cyclohexane : 3/3/1.5 + 1% N(Et)3); ESI-MS: 
m/z = 1853.1 [M+2Na]2+. 13C-NMR (CDCl3, 150 MHz), δ (ppm): 174.9-174.4 (C=O), 171.9-169.7 (C=O), 
143.7 (Ctriazole), 123.6 (CHtriazole), 122.8 (CHAr), 95.6 (C-1), 71.1, 68.0, 64.7(C-2, C-3, C-4, C-5), 61.2 
(CH2OAr/CH2Otriazole) 51.8 ( OCH3), 50.1 (CH2N3), 41.0 (CH2), 32.7 (CH2), 31.2 (CH3), 29.3 (CH2), 
25.9 (CH2), 24.3 (CH2), 20.7 (CH2),15.8 (C-6). HRMS(ESI/Q-TOF) m/z: [M+2Na]2+ calcd for 
C168H232N32Na2O52S4 1851.7586, found 1851.7592
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Tetramethylglycylglycinate-pseudopeptide p-tBu-thiacalixarene fucocluster 1,3-alternate 1. To a 
stirred solution of thiacalix 9 (0.320 g; 0.136 mmol) and compound 12 (0.121 g; 0.59 mmol) in 
THF/tBuOH/MeOH (5mL/5mL/5mL) was added a freshly prepared solution of Cu(I) (from CuSO4.5H2O 
(0.073 g) and sodium ascorbate (0.116 g) in H2O (5 mL)). The mixture was stirred for 3h at 60 °C. The 
resulting crude was purified by reverse-phase chromatography with eluent gradient of H2O/CH3CN to 
afford 1 as a yellow solid. Yield 0.229 g (53%); ESI-MS: m/z = 1600.7 [M+2Na]2+. 1H-NMR (MeOD, 
600 MHz), δ (ppm): 7.96-7.74 ( m, 8H , NH/CHtriazole), 7.27 (s, 8H, CHAr),4.79-7.70 (m, 4H, H-1), 4.69-
4.50 (m, 16H, OCH2triazole /CH2), 4.28 (m, 8H, CH2), 4.25-3.98 (m, 16H, CH2/CHFuc), 3.97-3.74 (m, 
12H, CH2/HFuc), 3.66-3.55 (m, 24H, CH2), 3.25 (s, 12H, OCH3), 3.21 (s, 4H,HFuc), 2.58-2.12 (m, 8H,CH2), 
1.98-1.71 (m, 8H,CH2), 1.67-1.46 (m, 16H, CH2), 1.30-1.16 (m, 8H, CH2), 1.07 (d, 12H, H-6, J = 5.9 Hz), 
0.99 (s, 36H, CH3). 13C-NMR (MeOD, 150 MHz), δ (ppm): 174.5-174.3 (C=O), 170.4-169.8 (C=O), 156.4 
(ArCOCH2), 146.5 (ArC(C(CH3)3)), 144.2 (Ctriazole), 128.1 (ArCSCAr), 127.2 (CHAr), 123.70 (CHtriazole), 
98.7 (C-1), 72.2, 70.2, 68.5, 66.5 (C-2, C-3, C-4, C-5), 65.8 (CH2OAr), 60.3 (OCH2triazole), 51.4 (OCH3), 
50.2 (CH2), 49.2 (CH2), 43.7 (CH2), 41.7 (CH2), 40.5(CH2), 33.8 (C(CH3)3), 32.1 (CH2), 30.3 (CH3), 29.6 
(CH2), 25.6 (CH2), 24.0 (CH2),15.3 (C-6). HRMS(ESI/Q-TOF) m/z: [M+2Na]2+ calcd for 
C144H208N32O40S4Na2 1599.6952, found: 1599.6948.
Tetrahydroxamic acid glycylglycinate-pseudopeptide p-tBu-thiacalixarene fucocluster 1,3-
alternate 2. Compound 1 (0.100g; 0.031 mmol), NH2OH (50%) (0.012 g; 0.38 mmol) and KCN (0.003 
g; 0.05 mmol) were dissolved in THF/MeOH (0.3 mL/0.3 mL) solvent mixture and stirred 7h at room 
temperature. The resulting crude was purified by reverse-phase chromatography with eluent gradient of 
H2O/CH3CN to afford 2 as a yellow solid. Yield 0.054 g (54%); ESI-MS: m/z = 1602.8 [M+2Na]2+. 1H-
NMR (MeOD, 600 MHz), δ (ppm): 8.22-7.9 ( m, 8H , NH/CHtriazole), 6.86 (s, 8H, CHAr), 4.93-4.52 (m, 
28H, H-1/OCH2triazole/CH2), 4.40-4.27 (m, 24H, CH2), 4.03-3.85 (m, 48H, CHFuc/CH2), 2.71-2.40 (m, 
16H, CH2), 2.35 (m, 4H, CH2), 1.91(m, 8H, CH2), 1.64 (m, 8H, CH2), 1.35 (m, 8H,CH2), 1.19 (d, 12H, 
H-6, J = 6.1 Hz), 1.10 (s, 36H, CH3). 13C-NMR (MeOD,, 150 MHz), δ (ppm): 175.9 (C=O), 171.7-171.0 
(C=O), 154.3 (ArCOCH2), 146.1 (ArC(C(CH3)3)), 134.8 (ArCSCAr), 126.4 (CHAr), 125.2 (CHtriazole), 
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100.1 (C-1), 73.3 , 73.0(CH2OAr), 71.5, 69.9, 67.8(C-2, C-3, C-4, C-5), 61.7 (OCH2triazole), 51.6 (CH2), 
51.2 (CH2), 45.2 (CH2), 41.8 (CH2), 41.8 (CH2), 34.8 (C(CH3)3), 33.6 (CH2), 32.0 (CH2), 30.97 (CH3), 
27.0 (CH2), 25.3 (CH2), 16.7 (C-6). HRMS(ESI/Q-TOF) m/z: [M+2Na]2+ calcd for C140H204N36Na2O40S4 
1601.6857, found 1601.6855.
Tetrabromo-tetramethylglycylglycinate-pseudopeptide p-tBu-calix[4]arene derivative 14. To a 
stirred solution of compound 7 (0.291g; 0.807 mmol) and tetraazidocalix 13 (0.180 g; 0.183 mmol) in 
THF/tBuOH (7.5mL/15mL) was added a freshly prepared solution of Cu(I) (from CuSO4.5H2O (0.091 g) 
and sodium ascorbate (0.145 g) in H2O (15 mL)). The mixture was stirred for 3h at 60 °C. After solvent 
evaporation, the crude product was extracted with CH2Cl2 and washed with brine. The organic layer was 
dried on MgSO4 and concentrated. Compound 14 was obtained after purification by column 
chromatography on silica gel (2/2/1: acetone/EtOAc/Cyclohexane, 1% N(Et)3) as a white solid. Yield 
0.253 g (57%); Rf  = 0.12 (SiO2, acetone/EtOAc/Cyclohexane, 2/2/1 + 1% N(Et)3); ESI-MS: m/z = 1235.9 
[M+2Na]2+. 1H-NMR (CDCl3, 300 MHz), δ (ppm): 8.1-7.6 (m, 8H, NH/ CHtriazole), 6.77 ( m, 8H, CHAr), 
4.52-4.34 (m, 8H, CH2), 4.30-4.11 (m, 12H, CH2/ArCH2Ar), 4.01 (m, 8H, CH2), 3.91 (m, 8H, CH2), 3.73-
3.63 (m, 12H, OCH3), 3.38 (m, 8H, CH2), 3.15 (dd, 4H, ArCH2Ar , J = 12,3 Hz), 2.61-2.44 (m, 12H, 
CH2), 2.32 (m, 4H, CH2), 1.83 (m, 8H, CH2), 1.58 (m, 8H, CH2), 1.41 (m, 8H, CH2), 1.05 (m, 36H, CH3). 
13C-NMR (CDCl3, 75 MHz), δ (ppm) : 174.1-173.7 (C=O), 170.4-169.1 (C=O), 152.8 (ArCOCH2), 145.3 
(ArC(C(CH3)3)), 143.7 (Ctriazole), 133.2 (ArCCH2CAr), 125.4 (CHAr), 123.52 (CHtriazole), 71.8 (OCH2), 
51.9(OCH3), 47.8 (CH2), 44.5 (CH2), 41.1 (CH2), 33.8 (CH2), 32.8 (CH2), 32.6 (CH2Br), 31.4(CH3), 31.1 
(CH2), 27.8 (CH2), 24.1 (CH2). HRMS(ESI/Q-TOF) m/z: [M+2Na]2+ calcd for C112H160Br4N20Na2O20 
1233.4324, found 1233.4350.
Tetraazido-tetramethylglycylglycinate-pseudopeptide p-tBu-calix[4]arene derivative 15. To a stirred 
solution of compound 14 (0.240 g; 0.099 mmol) in DMF (12 mL) was added NaN3 (0.077g; 1.186 mmol). 
After 12 h at 90 °C and evaporation, the crude product was extracted with CH2Cl2 and washed with brine. 
The organic layer was dried on MgSO4 and concentrated. Compound 15 was obtained after purification 
by column chromatography on silica gel (2/2/1 : acetone/EtOAc/Cyclohexane, 1% N(Et)3) as a yellow 
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solid.  Yield 0.213 g (95 %); Rf = 0.14 (SiO2, acetone/ EtOAc/ Cyclohexane : 2/2/1 + 1% N(Et)3). ESI-
MS: m/z = 1160.1 [M+Na]2+. 1H-NMR (CDCl3, 300 MHz), δ (ppm): 8.30-7.3 (m, 8H, CHtriazole/ NH), 
6.74 (m, 8H, CH Ar), 4.54-4.31 (m, 8H, CH2), 4.28-4.11 (m, 12H, ArCH2Ar/CH2), 4.08-3.94 (m, 8H, 
CH2), 3.96-3.78 (m, 8H, CH2O), 3.63(m, 12H,OCH3), 3.28-3.02 (m, 12H , CH2/ArCH2Ar), 2.65-2.22 (m, 
8H, CH2),1.72-1.44(m, 8H, CH2), 1.49-1.25 (m, 8H, CH2), 1.03 (m, 36H, CH3). 13C-NMR (CDCl3, 75 
MHz), δ (ppm) : 174.0/173.8 (C=O), 170.2/170.0 (C=O), 169.7/169.2 (C=O), 158.0 (ArCOCH2), 145.2 
(ArC(C(CH3)3)), 143.2 (Ctriazole), 133.1 (ArCCH2CAr), 125.3 (CHAr), 123.21 (CHtriazole), 71.8 (OCH2), 
52.2 (OCH3), 51.2 (CH2N3), 47.7 (CH2), 46.0 (CH2), 41.0 (CH2), 33.8 (C(CH3)3), 32.7 (CH2), 31.3 (CH3), 
31.0 (CH2), 29.6 (CH2), 28.4 (CH2), 26.3 (CH2), 24.4 (CH2). HRMS(ESI/Q-TOF) m/z: [M+2Na]2+ calcd 
for C112H160Br4N32O20Na2 1159.6135, found: 1159.6150.
Tetramethylglycylglycinate-pseudopeptide p-tBu-calix[4]arene fucocluster 3. To a stirred solution of 
calix 15 (0.32 g; 0.140 mmol) and compound 12 (0.125 g; 0.618 mmol) in THF/tBuOH/MeOH 
(5mL/5Ml/5mL) was added a freshly prepared solution of Cu(I) (from CuSO4.5H2O (0.070g) and sodium 
ascorbate (0.111g) in H2O (5 mL)). The mixture was stirred for 3h at 60 °C. The resulting crude was 
purified by reverse-phase chromatography with eluent gradient of H2O/CH3CN to afford 3 as a yellow 
solid. Yield 0.211 g (49%); ESI-MS: m/z = 1564.8 [M+2Na]2+. 1H-NMR (MeOD, 600 MHz), δ (ppm): 
8.19-8.00 (m, 8H, CHtriazole/NH), 6.86 (m, 8H, CH Ar), 4.81-4.55 (m, 20H, H-1/OCH2triazole /CH2), 4.45-
4.28 (m, 12H, CH2/ArCH2Ar), 4.18 (m, 8H, CH2), 3.99-3.94 (m, 12H, CH2/HFuc), 3.90 (m, 8H, CH2OAr), 
3.76 (s, 2H, HFuc), 3.72-3.65 (m, 16H, OCH3/HFuc ), 3.15 (d, 4H, ArCH2Ar, J =11.9 Hz), 2.54 (m, 16H, 
CH2), 1.89 (m, 8H, CH2), 1.64 (m, 8H, CH2), 1.34 (m, 8H, CH2), 1.19 (d, 12H, H-6, J = 6.1 Hz), 1.10 (m, 
42H, CH3/CH2). 13C-NMR (MeOD, 150 MHz), δ (ppm): 175.6 (C=O), 171.6-171.0 (C=O), 154.0 
(ArCOCH2), 145.9 (ArC(C(CH3)3)), 134.6 (ArCCH2CAr), 126.2 (CHAr), 124.9 (CHtriazole), 99.9 (C-1), 
73.4, 72.8 (CH2OAr), 71.3, 69.7, 67.6 (C-2, C-3, C-4, C-5), 61.5 (OCH2triazole), 52.5 (CH2), 51.4 (CH2), 
50.9 (CH2), 41.6 (CH2), 34.5 (C(CH3)3), 33.4 (CH2), 33.3 (CH2), 31.8 (CH2), 31.7 (CH3), 30.7 (CH2), 26.7 
(CH2), 25.1 (CH2), 16.4 (C-6). HRMS(ESI/Q-TOF) m/z: [M+2Na]2+ calcd for C148H216N32Na2O40 
1563.7824, found 1563.7870.
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2. Biological assessments.
SPR experiments measurement of DC-SIGN/ligands 1, 2 and 3 interaction. DC-SIGN ECD 
production and purification. DC-SIGN extracellular domain (DC-SIGN ECD) construct was produced 
and purified as described previously.54 Surface Plasmon Resonance analysis (SPR). competition assay. 
SPR experiments were performed on a Biacore 3000 using a CM4 chip, functionalized at 5 μL/min. BSA 
or BSA-Man were immobilized on flow cells using amine-coupling method. Fc1 was prepared as 
reference surface. Flow cell (Fc) 1, 2, 3 and 4 were acti- vated with 50 µL of a 0.2 M EDC/0.05 M NHS 
mixture. Fc1 was functionalized with bovine serum albumine (BSA), while Fc2, Fc3 and Fc4 were 
functionalized with mannosylated bovine serum albumine (BSA-(Manα1-3[Manα1-6]Man) from Dextra 
laboratories. Remaining activated groups were blocked with 30 µL of 1 M ethanolamine. After blocking, 
the four Fc were treated with 5 µL of 10 mM HCl to remove unspecific bound protein and 5 µL of 50 mM 
Na2EDTA to expose surface to regeneration protocol. The final immobilization levels for the Fc1, 2, 3 
and 4 are respectively 1541 RU, 1664 RU, 1376 RU and 1847 RU. For inhibition studies, 20 µM of DC-
SIGN ECD mixed with increasing concentrations of inhibiting compounds were prepared in a running 
buffer composed of 25 mM Tris pH 8, 150 mM NaCl, 4 mM CaCl2, 0.005% P20 surfactant, and 13 µL of 
each sample was injected onto the surfaces at a 5 μL/min flow rate. The resulting sensorgrams were 
reference surface corrected. The DC-SIGN binding responses were extracted from sensorgrams, converted 
to percent residual activity values (y) with respect to lectin alone binding, and plotted against 
corresponding compound concentration. The 4-parameter logistic model (See SI equation 1) was fitted to 
the plots, and the IC50 values were calculated using the values of fitted parameters (Rhi, Rlo, A1 and A2) 
(See SI equation 2).
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Inhibition of DC-SIGN/HCMV recombinant gB glycoprotein interaction. U937 parental cells 
(ATCC® CRL-1593.2™, LGC Standards, UK) or stably expressing the full length DC-SIGN lectin were 
propagated in RPMI 1640, 2mM glutamine, 10% FCS (HyClone/GE Healthcare, Wauwatosa, WI). Cells 
were resuspended in the binding buffer, TBS, 1 mM CaCl2, 2mM MgCl2, 0.1% bovine serum albumin 
(BSA) and then seeded in 96-well plates at 1.105 cells per well and Alexa 488®-conjugated recombinant 
HCMV gB (2 µg/ml) was then added to cells for 20 min at 4°C. Cells were washed thoroughly with cold 
binding buffer before being analyzed on a LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ) 
and the Flow Jo software (Tree Star, Ashland, OR).
Inhibition of EBOV cell line trans-infection. Recombinant viruses were produced in 293T cells by 
transfection with Lipofectamine 2000 (Life Technologies) following the manufacturer´s protocol. The 
viral construction was pseudotyped with Ebola virus (EBOV) envelope glycoprotein (GP) or Vesicular 
Stomatitis virus envelope GP (VSV-G) and expressed luciferase as a reporter of the infection.78,79 One 
day (18-24 h) before transfection, 5 x 106 293T were seeded onto 10 cm plates. Cells were cultured in 
DMEM medium supplemented with 10% heat-inactivated FBS, 25 mg Gentamycin, 2 mM L-glutamine. 
Supernatants containing GP-pseudotyped viruses were harvested 48h later, centrifuged to remove cell 
debris and stored in aliquots at -80º C. Infectious titers were estimated as tissue culture infectious dose 
per mL by limiting dilution of the lentivirus-containing supernatants on HeLa cells. Luciferase activity 
was determined by luciferase assay (Luciferase Assay System, Promega, Madison, WI) in a GloMax®-
Multi+ Detection System (Promega, Madison, WI, USA).
3. MMFF computational calculation. Spartan ’14 software was used to generate 6561 conformers of the 2 
thiacalix[4]arene repeat unit (O-alkylated 4-(tert-butyl)-2-mercaptophenol) in the gas phase. The relative steric 
energy of each conformer was determined by molecular mechanics using the Merck Molecular Force Field (MMFF) 
and the lowest 100 conformers were retained. The lowest energy conformer was replicated four times and linked to 
reform the thiacalix[4]arene. MMFF was used to optimize the geometry of the macrocycle. The resulting structure 
is as shown. It is notable that the most stable substituent conformer is very compact with dimensions down the axis 
of the thiacalixarene cavity of about 17 Å with dimensions perpendicular to the thiacalix[4]arene axis of 31 Å x 31 
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Å. None of the 100 lowest energy structures retained during analysis represented an extended conformer of the 
single repeat unit so one was constructed through forced bond rotation. Following geometry optimisation (MMFF) 
the structure was replicated and the extended form of the thiacalix[4]arene generated. Final geometry optimisation 
by MMFF gave the extended structure shown. Here the length of the thiacalixarene down the thiacalix[4]arene axis 
was approximately 55 Å (See SI, Figure S31) with perpendicular dimensions of 12 Å x 12 Å at the macrocycle’s 
annulus and 21 Å x 4 Å where the hydroxamic acid side arms emerge from the lower rim substituents.
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